Literature DB >> 19796521

Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006.

Margaret Warner1, Li Hui Chen, Diane M Makuc.   

Abstract

KEY
FINDINGS: Data from the National Vital Statistics System Mortality File. From 1999 through 2006, the number of fatal poisonings involving opioid analgesics more than tripled from 4,000 to 13,800 deaths. Opioid analgesics were involved in almost 40% of all poisoning deaths in 2006. In 2006, the rate of poisoning deaths involving opioid analgesics was higher for males, persons aged 35-54 years, and non-Hispanic white persons than for females and those in other age and racial/ethnic groups. In about one-half of the deaths involving opioid analgesics, more than one type of drug was specified as contributing to the death, with benzodiazepines specified with opioid analgesics most frequently. The age-adjusted death rate for poisoning involving opioid analgesics varied more than eightfold among the states in 2006. All material appearing in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796521

Source DB:  PubMed          Journal:  NCHS Data Brief        ISSN: 1941-4935


  85 in total

1.  Physician introduction to opioids for pain among patients with opioid dependence and depressive symptoms.

Authors:  Judith I Tsui; Debra S Herman; Malyna Kettavong; Daniel Alford; Bradley J Anderson; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2010-08-19

2.  Objective evidence of severe disease: opioid use in chronic pain.

Authors:  John A Zweifler
Journal:  Ann Fam Med       Date:  2012 Jul-Aug       Impact factor: 5.166

3.  ACMT Position Statement: The Use of Methadone as an Analgesic.

Authors: 
Journal:  J Med Toxicol       Date:  2016-06

4.  Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV.

Authors:  William C Becker; Kirsha Gordon; E Jennifer Edelman; Robert D Kerns; Stephen Crystal; James D Dziura; Lynn E Fiellin; Adam J Gordon; Joseph L Goulet; Amy C Justice; David A Fiellin
Journal:  AIDS Behav       Date:  2016-03

5.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

6.  Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.

Authors:  Margaret L Griffin; Dorian R Dodd; Jennifer S Potter; Lindsay S Rice; William Dickinson; Steven Sparenborg; Roger D Weiss
Journal:  Am J Drug Alcohol Abuse       Date:  2013-11-12       Impact factor: 3.829

7.  Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program.

Authors:  Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin
Journal:  Addiction       Date:  2015-08       Impact factor: 6.526

8.  Provider Experiences With the Identification, Management, and Treatment of Co-occurring Chronic Noncancer Pain and Substance Use in the Safety Net.

Authors:  Jamie Suki Chang; Margot Kushel; Christine Miaskowski; Rachel Ceasar; Kara Zamora; Emily Hurstak; Kelly R Knight
Journal:  Subst Use Misuse       Date:  2016-10-18       Impact factor: 2.164

9.  Prescription opioid use among addictions treatment patients: nonmedical use for pain relief vs. other forms of nonmedical use.

Authors:  Amy S B Bohnert; Anna Eisenberg; Lauren Whiteside; Amanda Price; Sean Esteban McCabe; Mark A Ilgen
Journal:  Addict Behav       Date:  2012-11-23       Impact factor: 3.913

10.  Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity.

Authors:  Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-05-08       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.